Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atea Pharmaceuticals Inc
(NQ:
AVIR
)
3.530
+0.050 (+1.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atea Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
September 13, 2024
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.
Via
Benzinga
Exposures
COVID-19
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
September 13, 2024
Via
Benzinga
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
June 05, 2024
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.
Via
Benzinga
AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024
May 14, 2024
AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
5 Under 10: Low Share Price, Debt Free, Lots Of Cash
May 13, 2024
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative.
Via
Talk Markets
Recap: Atea Pharmaceuticals Q4 Earnings
February 28, 2024
Via
Benzinga
Atea Pharmaceuticals Earnings Preview
February 27, 2024
Via
Benzinga
Atea Pharmaceuticals's Earnings Outlook
November 07, 2023
Via
Benzinga
Earnings Preview For Atea Pharmaceuticals
August 07, 2023
Via
Benzinga
Earnings Preview: Atea Pharmaceuticals
May 05, 2023
Via
Benzinga
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
January 09, 2024
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
May 30, 2023
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Preview: Atea Pharmaceuticals's Earnings
February 27, 2023
Via
Benzinga
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
September 26, 2022
Via
Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
September 13, 2022
Via
Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 30, 2023
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Via
Benzinga
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
May 22, 2023
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 22, 2023
Via
Benzinga
Recap: Atea Pharmaceuticals Q2 Earnings
August 08, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Short Volatility Alert: Atea Pharmaceuticals
May 18, 2022
On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The...
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 22, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via
Benzinga
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
May 22, 2023
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to...
Via
Benzinga
Atea Pharmaceuticals: Q1 Earnings Insights
May 10, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 15, 2023
On Wednesday, 35 stocks hit new 52-week lows.
Via
Benzinga
Atea Pharmaceuticals Earnings Preview
November 04, 2022
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea...
Via
Benzinga
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
July 07, 2022
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Via
Investor's Business Daily
Stocks Selling For Less Than Cash Per Share
July 03, 2022
How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially...
Via
Talk Markets
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.